The FDA's assessment of the bread recall has designated it as a Class II risk, which means the product "may cause temporary or medically reversible adverse health consequences." However, the classification is also used "where the probability of serious adverse health consequences is remote."

Taking medication for an allergic reaction? You might face severely itchy skin as a side effect of Zyrtec or Xyzal, according to a recent FDA warning for long-term users. Here's what you need to know.

FDA Commissioner Dr. Marty Makary joins Morning Joe to address the agency’s controversial decision to keep Juul e-cigarettes on the market, ongoing reviews of mifepristone, and the latest efforts on women's health and vaccine guidance.

Dr. George Tidmarsh, a Stanford pediatrics adjunct professor and former pharmaceutical executive, is FDA Commissioner Marty Makary’s pick to be the nation’s top drug regulator.

Replimune stock (ticker: REPL) cratered on Tuesday after the biotech said the U.S. Food and Drug Administration rejected an application seeking approval of its experimental skin cancer treatment.

The U.S. Food and Drug Administration ( FDA) has placed an immediate clinical hold on Sarepta Therapeutics' investigational gene therapy trials for limb girdle muscular dystrophy following three patient deaths potentially linked to the company's treatments.

A Food and Drug Administration expert panel has reignited a debate over whether hormone therapy should be used to treat menopause. The 12-person panel encouraged the use of the

FDA Commissioner Marty Makary announced that Dr. George Tidmarsh, a cancer and pediatric specialist, will direct the agency’s Center for Drug Evaluation and Research, which regulates the safety and effectiveness of all U.S. drugs.

An FDA advisory panel concludes that the efficacy of brexpiprazole, when started concurrently with sertraline, has not been established for the treatment of PTSD.